HTA43 Assessing the added value of fixed-dose combinations in non-communicable diseases a comparative HTA analysis across Canada, Scotland, France, and Germany (2014-2024)
Alani, A. H.
, Mills, M. & Kanavos, P.
(2025).
HTA43 Assessing the added value of fixed-dose combinations in non-communicable diseases a comparative HTA analysis across Canada, Scotland, France, and Germany (2014-2024).
Value in Health,
28(6, Supplement 1), S254.
https://doi.org/10.1016/j.jval.2025.04.1054
, Mills, M. & Kanavos, P.
(2025).
HTA43 Assessing the added value of fixed-dose combinations in non-communicable diseases a comparative HTA analysis across Canada, Scotland, France, and Germany (2014-2024).
Value in Health,
28(6, Supplement 1), S254.
https://doi.org/10.1016/j.jval.2025.04.1054
To examine factors influencing approval and reimbursement of fixed-dose combinations (FDCs) for non-communicable diseases (NCDs) across four HTA agencies (SMC, HAS, G-BA, CDA) from 2014-2024. The analysis covered clinical and economic evidence, stakeholder perspectives, and implementation factors for FDCs targeting diabetes mellitus (DM), asthma, chronic obstructive pulmonary disease (COPD), and cardiovascular diseases (CVDs).